Lenvatinib: Role in thyroid cancer and other solid tumors.
Houston, United States. In Cancer Treat Rev, Jan 2016
Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor α (PDGFRα).
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Villejuif, France. In N Engl J Med, Dec 2015
BACKGROUND: Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.
Human Papillomavirus-Negative Pharyngeal Cancer.
London, United Kingdom. In J Clin Oncol, Nov 2015
In this review, we discuss the evidence for the current treatment of locally advanced human papillomavirus-negative HNSCC, as well as investigational therapies, such as hypoxia modification, molecular targeting of epidermal growth factor receptor family, vascular endothelial growth factor receptor or DNA damage response proteins in combination with radiation therapy.
Overview of fundamental study of pazopanib in cancer.
Tianjin, China. In Thorac Cancer, 2014
Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug.